Nature Reviews Rheumatology

Article	Citations
Inflammatory arthritis affects men’s fertility	525
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	401
Polygenic risk scores outperform other tests in AS	342
Bimekizumab effective across the axSpA spectrum	314
No benefit from adding MTX to ustekinumab	275
Targeting articular Mmp13 in OA	255
Low-dose rituximab can go even lower	248
Genome-wide mutagenesis reported in systemic sclerosis	227
Rheumatic diseases on the rise	209
Osteoarthritis risk factors differ between sexes	205
A role for TGFβ and EBV in MIS-C pathogenesis	175
Biological and clinical roles of IL-18 in inflammatory diseases	166
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	160
New drug formulation reduces bone loss	159
Ageing stem cells hold the key to age-related bone degeneration	156
FOXP3 splice variant is associated with autoimmune disease	144
Towards better management of sterile bone inflammation	141
Use of platelet-rich plasma for knee OA not supported by RCT results	140
Which NSAIDs are best for OA treatment?	132
Down syndrome: insights into autoimmune mechanisms	125
Inflammation across tissues: can shared cell biology help design smarter trials?	119
MIS-C: myths have been debunked, but mysteries remain	110
Urchin-like nanoparticles for miRNA therapy of OA	103
2021 ACR guideline for JIA reflects changes in practice	101
The value of comparative efficacy studies in informing rheumatology guidelines	100

The 2022 ACR vaccination guideline: a call-to-action	100
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	95
To choose or not? The value of discrete-choice experiments in rheumatology	94
Appraising the evolving landscape of protease inhibition in osteoarthritis	93
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	92
Co-trimoxazole reduces mortality in anti-MDA5-DM	91
Low-dose glucocorticoids benefit seniors with RA	89
Rheumatology in the digital health era: status quo and quo vadis?	84
Fumarate drives interferon release in systemic sclerosis monocytes	82
S100A4 inhibition targets fibrosis in SSc	81
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	80
Wnt-induced IGF1 drives OA	76
Calprotectin tracks tocilizumab-treated RA	76
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	75
Author Correction: Proposals for the rheumatological use of JAK inhibitors	74
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	74
Rheumatic diseases and metabolism: where centre and periphery meet	73
Guiding ILD management in systemic autoimmune rheumatic diseases	73
A direct link between SARS-CoV-2 and bone loss	71
Low back pain is a growing concern	69
Antibiotics keep rheumatic heart disease at bay	68
sCD13 role in arthritis mediated via bradykinin receptor	68
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	68
Targeting the IVD clock to halt degeneration	65
Insights into IVDD pathogenesis in 2024	64
Erosive cargo from synovial fibroblasts	63
Which DMARD for ICI-associated arthritis?	62
PGE2 receptor antagonist has potential to treat osteoarthritis	60
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases	58
Macrophage-coated nanocarriers for gouty arthritis	58
ERAP1 and the return of the UPR in ankylosing spondylitis	58
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	58
A path towards personalized medicine for autoinflammatory and related diseases	57
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	57
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	55
CAR T cells induce drug-free SLE remission	55
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	54
Antibodies induce fibromyalgia symptoms	53
PPIs linked to increased risk of knee replacement	52
Blocking CDK7 attenuates inflammatory arthritis	52
RA risk from occupational inhalation	51
TASL has a key role in SLE	50
Mysteries of kidney-protecting parasitic infection revealed	49
All fibroblasts are equal, but some are more equal than others	47
Two sides of management recommendations for psoriatic arthritis	47
Is air pollution linked with poor response to biologics?	47
Improving the design of RCTs in non-radiographic axial spondyloarthritis	47
A critical view of WHO guidelines on management of low back pain	47
Repolarizing macrophages using antagomirs	45
Profiling joint tissues at single-cell resolution: advances and insights	44

A leading role for interferon as a treatment target in Sjögren syndrome	43
New hope for B cell-targeting therapy in pSS	43
New refinements aim to optimize articular cartilage tissue engineering	43
New developments in electronic health record analysis	42
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	42
CXCL5 effective in mouse model of SLE	40
DNA methylation inhibitor resets tolerance in autoimmune arthritis	40
Treg cell-inducing nanoparticles show promise for treating OA	40
Author Correction: Glycobiology of rheumatic diseases	37
Piezo1 induces new bone formation in AS	37
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	37
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	35
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	34
AhR promotes suppressor cell function in Sjögren syndrome	34
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	33
APOE in fat pad and synovium contributes to knee OA	33
Sex- and gender-based personalized medicine in rheumatology	33
Pathogenic antibodies target stromal antigens in RA	33
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	31
Are DNA–HLA class II interactions the missing link in SLE?	31
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	31
Critical appraisal of serum urate targets in the management of gout	29
Stromal cells implicated in RA genetic risk	29
Imaging for prediction of RA development	28
B cell X-chromosome inactivation is faulty in SLE	27
HLA autoimmunity risk alleles influence T cell receptor sequences	26
New OA risk factors and drug targets revealed	26
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	26
BiTE therapy for rheumatic diseases	25
FABP4 exacerbates RA	24
Shifting the SLE management paradigm: challenges and implications	23
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	22
Post-transcriptional checkpoints in autoimmunity	21
Mechanisms and clinical implications of intervertebral disc calcification	20
COVID-19 linked to rise in anti-MDA5 autoimmunity	19
Guselkumab effective through 2 years in PsA trial	19
PLG nanoparticles target inflammatory monocytes in SSc	18
Detachment promotes RA synovial fibroblast survival and invasiveness	18
Multi-omics reveals distinct MPA subtypes	18
Busting the myth of methotrexate chronic hepatotoxicity	18
Adropin inhibits fibrosis in SSc	18
Notch signalling mediates OA pain in mice	18
Complement therapeutics are coming of age in rheumatology	17
State-of-the-art evidence in the treatment of systemic sclerosis	17
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	17
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	16
Tildrakizumab shows promise in phase IIb study	16
The potential contribution of in silico studies to improved treatment of osteoarthritis	16
Citrulline immunity in RA: CD8+ T cells enter the scene	16
How the COVID-19 pandemic has affected rheumatology research	15
Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer	15
Treatment of non-systemic juvenile idiopathic arthritis	15
Update on the pathophysiology and treatment of primary Sjögren syndrome	14
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	14
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	13
Primary care rheumatology: towards sustainable development in health	13
Shedding light onto the immunometabolic effects of glucocorticoids	13
Targeting calcium-related mechanotransduction in early OA	13
UNC93B1 variants promote SLE via TLR activation	13
The immune health metric as an indicator of health and disease	13
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	13
Bone-modifying drugs slow OA progression	12
Genome editing to define the function of risk loci and variants in rheumatic disease	12
No benefit to intensive urate lowering in gout	12
Glycosylation switch in synovial fibroblasts promotes ECM degradation	12
Undiagnosed axSpA is prevalent in IBD	12
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	12
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	11
The PU.1– IL-9 axis in TH9 cells promotes RA	11
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	11
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	11
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	11
Combination therapy for Behçet uveitis	11
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	10
Interleukin-2 and regulatory T cells in rheumatic diseases	10
Reversal of inflammatory priming prevents arthritic flares	10
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	9
Rheumatology resources need reform to represent all patients	9
T cell differentiation in Sjögren syndrome is regulated by TOX	9
Evidence-Based Guideline for the management of osteoporosis in men	9

Advances in the calculation of minimal important change estimates for patient-reported outcome measures	9
Paediatric glucocorticoid toxicity index: new possibilities in assessment	9
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	9
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	9
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	9
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer	8
Disease stratification in GCA and PMR: state of the art and future perspectives	8
Novel TLR7 variant causes lupus	8
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy	7
MIS-C: how do patients fare 6 months on?	7
Pregnancy outcomes improving in axSpA	7
Imaging in inflammatory arthritis: progress towards precision medicine	7
Real-world data provide insights into PsA treatment patterns	7
CD38hiCD8+ T cells characterize ICI-mediated arthritis	7
Treat-to-target or treat-to-dissolve strategy to improve gout treatment	7
Age-related mechanisms in the context of rheumatic disease	7
PPM1A: TGFβ regulator and therapeutic target in OA	7
PJP prophylaxis with rituximab	6
A new immunometabolic perspective of intervertebral disc degeneration	6
Benralizumab noninferior to mepolizumab for EGPA	6
GCA management guidelines — vive la différence?	6
Gut T cells help mediate fracture healing	6
Kindlin-2 reduces IVD inflammation	6
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?	6
Macrophages hit a nerve in painful joint venture	6
Annexin A1 could help prevent periprosthetic bone loss	6
Author Correction: New genes, pathways and therapeutic targets in autoinflammatory diseases	6
Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis	5
New treatments for amyloidosis	5
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity	5
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout	5
Knee OA progression risk with steroids or HA	5
New guideline for integrative approaches to RA management	5
Relapsing polychondritis: clinical updates and new differential diagnoses	5
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity	5
ZEB2 promotes formation of age-related B cells	5
Optimizing methotrexate withdrawal during COVID vaccination	5
Lyme arthritis: linking infection, inflammation and autoimmunity	5
High risk of autoimmune diseases after COVID-19	4
New screening tool developed to aid diagnosis of axial PsA	4
ETS1 implicated in polarization of tissue-destructive fibroblasts	4
Mechanism of B cell survival in lupus nephritis	4
Limitations of the updated EULAR recommendations for osteoarthritis	4
Lupus nephritis-related chronic kidney disease	4
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	4
Pregnancy outcomes in SLE have not improved	4
IRAK4 inhibitor attenuates inflammation	4
Sarcoidosis: can tofacitinib slay the dragon?	4
Keep your Sox on, chondrocytes!	4
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	4
Does psoriasis treatment affect PsA development?	4
Integrin signalling in joint development, homeostasis and osteoarthritis	4
Collagen-binding antibody prevents arthritis	4
JAK inhibitors improve RA pain	4
A basket genetic trial of the vasculitides	3
Publisher Correction: IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	3
Metabolic reinvigoration of immune tolerance	3
New evidence for the ‘cusp theory’ to explain HLA associations in SLE	3
Pentose phosphate pathway metabolite restores T cell balance in SLE	3
Nasal chondrocytes enable cartilage repair in OA joints	3
Is X chromosome inactivation a cause or effect of SLE?	3
The peculiar features, diversity and impact of citrulline-reactive autoantibodies	3
The role of mitochondria in rheumatic diseases	3
How muscle influences bone health	3
Understanding synovial cell diversity in post-traumatic OA	3
A subset of ITGA5+ synovial fibroblasts alter the inflammatory niche in RA	3
Joint location matters for TNF inhibitor treatment in PsA	3
Targeting IL-23 for axial disease in PsA	3
A comprehensive guide for managing the reproductive health of patients with vasculitis	3
PR3 triggers granuloma formation in GPA	3
Integrin-mediated ILC2 adhesion protects against lupus nephritis	3
SLE risk variant regulates IRF8 expression	3
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	3
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress	3
T cells in Sjögren disease	3
NK cells induce a pro-inflammatory phenotype in RA synovial fibroblasts	3
Reply to: TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out	3
Joint-on-chip platforms: entering a new era of in vitro models for arthritis	3
The therapeutic potential of immunoengineering for systemic autoimmunity	3
Targeting UHRF1 in RA	3
VEXAS syndrome more common than originally thought?	3
Cardio-rheumatology: it’s time to collaborate	3
Reply to: Hypothetical model ignores many important pathophysiologic mechanisms in fibromyalgia	3
CXCL7 promotes bone erosion in RA	2
Mito+ RBCs prompt IFN and IL-1β release by SLE monocytes	2
Global epidemiology of rheumatoid arthritis	2
Somatic mutations linked to osteoporosis	2
A safe and effective treatment for MAS	2
Mannosylation is a cause and target in lupus nephritis	2
Pre-RA autoantibodies recognize arthritogenic gut bacterium	2
Genetically transitional disease: conceptual understanding and applicability to rheumatic disease	2
Striking a balance in rheumatoid arthritis prevention trials	2
proBDNF blockade modulates SLE	2
Psoriatic arthritis from a mechanistic perspective	2
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis	2